Knight Therapeutics Inc.
GUD.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 73.93% | 37.98% | 30.46% | 11.10% | -4.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 73.93% | 37.98% | 30.46% | 11.10% | -4.46% |
| Cost of Revenue | 53.86% | 21.50% | 37.79% | 28.20% | 11.32% |
| Gross Profit | 104.56% | 61.05% | 22.77% | -6.34% | -21.45% |
| SG&A Expenses | 35.99% | 40.62% | 20.56% | 22.78% | 5.92% |
| Depreciation & Amortization | 59.84% | 30.69% | 36.83% | -9.09% | -18.14% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 51.98% | 27.64% | 34.43% | 20.56% | 4.76% |
| Operating Income | 297.16% | 310.66% | -80.03% | -180.74% | -295.54% |
| Income Before Tax | 3,768.38% | 43.11% | -412.20% | -2,265.11% | 94.75% |
| Income Tax Expenses | 140.46% | 183.21% | 254.78% | -211.30% | 6.56% |
| Earnings from Continuing Operations | 521.98% | -17.18% | -4,517.98% | -542.81% | 145.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 521.98% | -17.18% | -4,517.98% | -542.81% | 145.15% |
| EBIT | 297.16% | 310.66% | -80.03% | -180.74% | -295.54% |
| EBITDA | 356.88% | 155.96% | 9.90% | -52.58% | -62.73% |
| EPS Basic | 528.76% | -16.25% | -4,700.00% | -554.29% | 145.95% |
| Normalized Basic EPS | 70,900.00% | 189.87% | -0.97% | -1,425.00% | -100.45% |
| EPS Diluted | 572.66% | -10.88% | -4,933.33% | -543.84% | 141.74% |
| Normalized Diluted EPS | 70,500.00% | 189.87% | -0.97% | -1,425.00% | -100.45% |
| Average Basic Shares Outstanding | -1.19% | -1.19% | -1.46% | -1.68% | -1.51% |
| Average Diluted Shares Outstanding | -1.15% | -1.07% | -1.46% | -1.68% | -1.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |